Financhill
Buy
68

DCTH Quote, Financials, Valuation and Earnings

Last price:
$16.10
Seasonality move :
-1.39%
Day range:
$15.92 - $16.63
52-week range:
$6.33 - $18.23
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.89x
P/B ratio:
6.99x
Volume:
550.9K
Avg. volume:
469.7K
1-year change:
105.22%
Market cap:
$561.1M
Revenue:
$37.2M
EPS (TTM):
-$0.50

Analysts' Opinion

  • Consensus Rating
    Delcath Systems has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $24.08, Delcath Systems has an estimated upside of 49.46% from its current price of $16.11.
  • Price Target Downside
    According to analysts, the lowest downside price target is $21.00 representing -30.35% downside risk from its current price of $16.11.

Fair Value

  • According to the consensus of 4 analysts, Delcath Systems has 49.46% upside to fair value with a price target of $24.08 per share.

DCTH vs. S&P 500

  • Over the past 5 trading days, Delcath Systems has underperformed the S&P 500 by -3.26% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Delcath Systems does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Delcath Systems has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Delcath Systems reported revenues of $19.8M.

Earnings Growth

  • Delcath Systems has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Delcath Systems reported earnings per share of $0.03.
Enterprise value:
502.2M
EV / Invested capital:
6.26x
Price / LTM sales:
9.89x
EV / EBIT:
--
EV / Revenue:
9.33x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-66.25x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$45.7M
Return On Assets:
-26.74%
Net Income Margin (TTM):
-26.38%
Return On Equity:
-40.28%
Return On Invested Capital:
-37.34%
Operating Margin:
3.25%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue $2.9M $4.6M $53.9M $3.1M $19.8M
Gross Profit $2.1M $3.3M $45.7M $2.2M $16.9M
Operating Income -$33.8M -$40.1M -$1.5M -$10.3M $642K
EBITDA -$33.6M -$39.7M -$3.6M -$10.2M $709K
Diluted EPS -$3.81 -$2.50 -$0.50 -$0.45 $0.03
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $30.2M $25.4M $29M $33.6M $84.3M
Total Assets $32.3M $27.3M $30.6M $36.1M $87.3M
Current Liabilities $10.1M $8.7M $13.4M $13.3M $5.3M
Total Liabilities $12.3M $22.1M $43.7M $21.5M $7.1M
Total Equity $20M $5.2M -$13.1M $14.6M $80.2M
Total Debt $2M $15.8M $9.6M $7.4M --
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations -$22.8M -$36.6M -$6.9M -$9.6M $2.2M
Cash From Investing -$120K -$15M -$30.8M $4.7M -$25.1M
Cash From Financing $26.8M $39.1M $38.6M $4M $3.3M
Free Cash Flow -$23M -$36.6M -$7.6M -$9.6M $2.1M
DCTH
Sector
Market Cap
$561.1M
$34.8M
Price % of 52-Week High
88.37%
44.2%
Dividend Yield
0%
0%
Shareholder Yield
0.47%
-0.6%
1-Year Price Total Return
105.22%
-41.1%
Beta (5-Year)
0.722
0.659
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $16.77
200-day SMA
Buy
Level $11.78
Bollinger Bands (100)
Buy
Level 11.83 - 15.59
Chaikin Money Flow
Buy
Level 2.4M
20-day SMA
Buy
Level $14.46
Relative Strength Index (RSI14)
Buy
Level 61.13
ADX Line
Buy
Level 38.46
Williams %R
Neutral
Level -30.9489
50-day SMA
Buy
Level $13.17
MACD (12, 26)
Buy
Level 1.64
25-day Aroon Oscillator
Buy
Level 84
On Balance Volume
Neutral
Level 1.5M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (21.7458)
Buy
CA Score (Annual)
Level (-0.11)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (5.6646)
Buy
Piotroski F Score (Annual)
Level (7)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Stock Forecast FAQ

In the current month, DCTH has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DCTH average analyst price target in the past 3 months is $24.08.

  • Where Will Delcath Systems Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Delcath Systems share price will rise to $24.08 per share over the next 12 months.

  • What Do Analysts Say About Delcath Systems?

    Analysts are divided on their view about Delcath Systems share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Delcath Systems is a Sell and believe this share price will drop from its current level to $21.00.

  • What Is Delcath Systems's Price Target?

    The price target for Delcath Systems over the next 1-year time period is forecast to be $24.08 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is DCTH A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Delcath Systems is a Buy. 4 of 4 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of DCTH?

    You can purchase shares of Delcath Systems via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Delcath Systems shares.

  • What Is The Delcath Systems Share Price Today?

    Delcath Systems was last trading at $16.10 per share. This represents the most recent stock quote for Delcath Systems. Yesterday, Delcath Systems closed at $16.11 per share.

  • How To Buy Delcath Systems Stock Online?

    In order to purchase Delcath Systems stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will DigitalOcean Stock Bounce Back?
Will DigitalOcean Stock Bounce Back?

DigitalOcean (NYSE:DOCN) has run into the proverbial brick wall with…

Where Will Cognizant Stock Be In 5 Years?
Where Will Cognizant Stock Be In 5 Years?

Cognizant Technologies (NASDAQ:CTSH) is a global provider of IT services…

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

NVIDIA (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO) are two of the hottest…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 38x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
33
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Buy
60
MRUS alert for May 24

Merus NV [MRUS] is up 32.55% over the past day.

Buy
57
RGC alert for May 24

Regencell Bioscience Holdings [RGC] is up 28.43% over the past day.

Buy
90
OKLO alert for May 24

Oklo [OKLO] is up 23.11% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock